NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Car-T study: Ok, finally, by the way, the authors concede that the reason Car-T likely failed in that patient is that tumors 9, 10, 11, etc, did not have cancer cells with the antigen the car-t was targeting.

In other words, in one of the 75% GBM patients, in a 65 patient trial*, tumor escape occurred within 7.5 months of car-t treatment initiation, two months of which included a complete response (in five tumors) before treatment failure via tumor escape.

The cause of this tumor recurrence is currently under investigation, with preliminary results suggesting decreased expression of IL13Ra2 (Fig. S8 in the Supplementary Appendix).

*no other GBM patients in that trial had a partial or complete response.